ReviewChirality2026
Recent Progress in the Total Synthesis and Biosynthesis of Arborisidine.
Review in Chirality, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As a significant representative of monoterpenoid indole alkaloids (MIAs) and 1,1-disubstituted tetrahydro-β-carboline (THβC) alkaloids, Arborisidine, since its discovery in 2016 by Kam and coworkers, has emerged as a focal molecule in the field of total synthesis due to its unique pentacyclic cage-like skeleton and the quaternary carbon center at C(16). Multiple research groups have conducted in-depth investigations into its total synthesis and successfully developed novel synthetic strategies. These studies have not only advanced the total synthesis and structural modification of this class of MIA natural products but also provided scientific approaches for structure-activity relationship (SAR) studies. Furthermore, with the rapid advancement of synthetic biology, investigations into the biosynthetic pathways of these alkaloids have not only offered innovative synthetic strategies for chemical synthesis but also delivered precise tools for structure-directed modification, thereby significantly accelerating structure-based drug design (SBDD). Based on this background, this review summarizes the recent advances in the total synthesis and biosynthetic studies of arborisidine, aiming to provide scientific insights for the synthesis of other family members through comparative analysis of diverse synthetic strategies, as well as to offer methodological support for drug design based on this structural framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.